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298Objective: The purpose of this study was to examine the changes in expression of angiotensin II receptor type 1/2
in left or right atrial tissue from patients with rheumatic valvular disease with or without atrial fibrillation.
Methods:Atrial tissue samples were obtained from 39 patients with rheumatic mitral valve disease during cardiac
surgery. Among these patients, there were 25 with atrial fibrillation and 14 with sinus rhythm. The level of an-
giotensin II receptor type 1 or type 2 mRNA transcription was measured by means of a semiquantitative reverse
transcription–polymerase chain reaction technique. Expression of angiotensin II receptor type 1 or type 2 protein
was detected by means of immunohistochemistry assay and Western blot analysis.
Results: The inner diameter of the left atrium was clearly enlarged in the atrial fibrillation group in comparison
with that seen in the sinus rhythm group. The expression levels of both angiotensin II receptor type 1 mRNA and
protein in the left atrial tissue were significantly increased in the patients with atrial fibrillation compared with
those seen in patients with sinus rhythm (P< .05). Interestingly, the comparison of angiotensin II receptor
type 2 expression levels in the left atrial tissue between these 2 groups is not statistically significant. In addition,
the results of angiotensin II receptor type 1 or 2 expression in the right atrial tissue did not show any obvious
change in the patients with atrial fibrillation versus those with sinus rhythm.
Conclusions: Expression of angiotensin II receptor type 1 but not type 2 is highly upregulated only in the left
atrial tissue of patients with rheumatic valvular disease with atrial fibrillation. This suggests that there is a possible
pathophysiologic role of the renin–angiotensin system in patients with atrial fibrillation and that a series of effects
mediated by the activation of angiotensin II receptor type 1 in the left atrial tissue might be one of the molecular
mechanisms involved in the process of atrial remodeling in atrial fibrillation. (J Thorac Cardiovasc Surg
2010;140:298-304)Atrial fibrillation (AF) in clinical practice is the most com-
mon arrhythmia associated with increasing morbidity and
mortality mainly caused by heart failure and stroke. Recent
studies have shown that angiotensin-converting enzyme in-
hibitor (ACEI) or angiotensin receptor blocker (ARB) ther-
apy was beneficial in the management of AF and that the
renin–angiotensin system (RAS) was regulated in the pro-
cess of AF. However, the profile of angiotensin II receptor
expression in atria with fibrillation still remains controver-
sial.1,2 Our current investigation sought to determine
whether there exists a difference in expression levels be-
tween angiotensin II receptor type 1 (AT1-R) and angioten-
sin II receptor type 2 (AT2-R) in left atrial (LA) or right atrial
(RA) tissue from patients with rheumatic valve disease with
or without AF.e Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.
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The Journal of Thoracic and Cardiovascular SurgMATERIALS AND METHODS
Inclusion Criteria
Patients with rheumatic valve disease with AF or sinus rhythm (SR) un-
derwent cardiac surgery for heart valve replacement (AF group, n¼ 25; SR
group, n¼ 14). Patients in the AF group had persistent AF lasting more than
6 months without paroxysmal and self-terminating episodes. There was no
observed paroxysmal AF in the SR group. All patients provided informed
consent for retrieval of cardiac biopsy samples. Procedures were carried
out according to our institutional ethical guidelines and the Declaration of
Helsinki. All patients who received ultrasonic cardiographic examination
did not have a history of taking ACEIs or ARBs. LA or RA tissues were ob-
tained from the left or right auricle during cardiac surgery. Each sample was
divided into 2 parts, one of which was quickly transferred into liquid nitro-
gen and stored at80C, which prepared for both the assay of AT1R orAT2R
mRNA expression by means of reverse transcription–polymerase chain re-
action (RT–PCR) and analysis of protein levels by means of Western blot-
ting. The rest of the sample was fixed with formalin for immunohistologic
analysis.
RT–PCR
Total RNA was extracted from the frozen atrial tissue by using Trizol re-
agent (Sigma, St Louis, Mo). The concentration and purity of the RNA was
determined by measuring the absorbance at 260 and 280 nm. The optical
density 260/280 ratio of each total RNA sample was approximately 2.0.
The final concentration of total RNA was adjusted to 1 mg/mL. Each
cDNA template was reverse transcribed with the Reverse Transcription Sys-
tem kit (Promega, Madison, Wis). The following protocol is optimized to
generate a first-strand cDNA template for RT–PCR reaction. First, 4 mL
of total RNA sample was mixed with 10.5 mL of diethylpyrocarbonateery c August 2010
Abbreviations and Acronyms
ACE ¼ angiotensin-converting enzyme
ACEI ¼ angiotensin-converting
enzyme inhibitor
AF ¼ atrial fibrillation
ARB ¼ angiotensin receptor blocker
AT1-R ¼ angiotensin II receptor type 1
AT2-R ¼ angiotensin II receptor type 2
GAPDH ¼ glyceraldehyde-3-phosphate
dehydrogenase
LA ¼ left atrium
PBS ¼ phosphate-buffered saline
PCR ¼ polymerase chain reaction
RA ¼ right atrium
RAS ¼ renin–angiotensin system
RT–PCR ¼ reverse transcription–polymerase
chain reaction
SR ¼ sinus rhythm
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DH2O, and 0.5 mL of oligo dT–adaptor primer was incubated at 70
C for 5
minutes. Second, after 5 minutes, the mixture was supplemented with 4
mL of diethylpyrocarbonate H2O, 6 mL of 5 3 RNA polymerase chain re-
action (PCR) buffer, 3 mL of deoxyribonucleoside triphosphate (10
mmol/L), 0.7 mL of RNase inhibitor, and 1.3 mL of M-MLV and was again
incubated at 37C for 1 hour.AT1R andAT2R gene expressionwas analyzed
bymeans of RT–PCR. The specific primers used in this study (Table 1) were
designed by Shanghai Sang Gong Company. Expression of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)mRNA was used as an internal con-
trol. PCRwas performed in a total volume of 25 mL for each reaction, which
included 1 mL of the first-strand cDNA synthesis mixture, 5 mL of 53 PCR
Buffer, 0.25 mL of Taq DNA Polymerase, 0.5 mL of the respective target
gene primer (20 mmol/L), or 0.1 mL of GAPDH primer (20 mmol/L). The
PCR reaction was programmed as follows. First, initial denaturation was
performed at 94C for 5 minutes. Second, the samples were subjected to
35 cycles, including denaturation at 94C for 30 seconds, primer annealing
at 58C (AT1-R) or 60C (AT2-R) for 30 seconds, and extension at 72C for
60 seconds. At the end of 35 cycles, the samples were kept at 72C for ex-
tension for 7 minutes. After PCR amplification, 10 mL of PCR product from
each sample was electrophoresed through a 2% agarose gel, and amplified
bands were detected by means of ethidium bromide staining. The relative
amount of angiotensin II receptors in each sample was investigated by com-
parison of gray scale values of target genes with the gray scale signal of
GAPDH. The GAPDH value was used as an adjusting factor to ensure
that the same amount of cellular genes in each patient was determined.
The ratio of angiotensin II receptor/GAPDH from each patient was usedTABLE 1. PCR information for AT1R, AT2R, and GAPDH genes
Target genes Primer
AT1R Upper: 50-GATGATTGTCCCAAAGCTGG-30
Lower: 50-TAGGTAATTGCCAAAGGGCC-30
AT2R Upper: 50-GGGCTTGTGAACATCTCTGG-30
Lower: 50-GTAAATCAGCCACAGCGAGG-30
GAPDH Upper: 50-TCCATGACAACTTTGGCATCGTGG -
Lower: 50- GTTGCTGTTGAAGTCACAGGAGAC
PCR, Polymerase chain reaction; AT1-R, angiotensin II receptor type 1; AT2-R, angiotensi
The Journal of Thoracic and Cato calculate possible differences in expression of angiotensin II receptors
(Table 2).Immunohistochemistry
Immunohistochemical detection of AT1-R or AT2-R expression was
performed on 5-mm transverse paraffin sections. Sections were deparaffi-
nized with xylene, placed in 100% ethanol, and then rehydrated through
graded ethanol solutions. Endogenous peroxidase activity was quenched
by means of incubation with 3% hydrogen peroxide in phosphate-buffered
saline (PBS). Antigen retrieval was accomplished by microwaving sections
in citrate buffer (pH 6.0). Then the sections were washed with PBS (pH 7.0).
The sections were incubated with 30 mL of primary antibody (rabbit anti
AT1-R or antiAT2-R receptor polyclonal antibody, 1:50) at 37C for 1
hour. After primary antibody incubation, the sections were washed with
PBS 3 times (for 5 minutes each) and then incubated with secondary anti-
body at 37C for 20 minutes. At the end, these sections were counterstained
with hematoxylin and mounted. We used Image-Pro Plus 5.02 (Media Cy-
bernetics, Inc, Bethesda, Md) to calculate the integrated optical density to
quantitate the AT1-R or AT2-R protein expression (Table 3).
Western Blot Analysis
To determine whether there exists a difference between the SR and AF
groups in LA or RA tissue’s AT1-R or AT2-R protein levels, Western blot-
ting was performed on tissue homogenates of LA or RA (70 mg). Briefly,
total homogenate was prepared by using a triple-detergent lysis buffer
with the protease inhibitors phenylmethylsulfonyl fluoride and aprotinin.
One hundred fifty microliters of homogenate was mixed with 50 mL of load-
ing buffer (1:4) and heated to 100C for 5 minutes, and 30 mL of the pre-
pared sample was then loaded into each lane. Protein was resolved on
a 7.5% acrylamide trisglycine gel and blotted onto a polyvinylidene difluor-
ide membrane and then detected with rabbit anti–AT1-R or rabbit anti–
AT2-R (BOSTER; dilution 1:100) and horseradish peroxidase–conjugated
secondary antibody with chemiluminescent substrate. a-Tubulin was used
as an internal control. The relative amount of angiotensin II receptors in
each sample was investigated by means of comparison of gray scale values
of target protein with the gray scale signal of a-tubulin. The a-tubulin value
was used as an adjusting factor to assure that the same amount of cellular
protein in each patient was determined. The ratio of angiotensin II recep-
tor/a-tubulin from each patient was used to calculate possible differences
in expression of angiotensin II receptors (Table 4 and Figure 1).
Data Analysis
Data are presented as means standard errors, which were compared by
using independent-samples t tests.RESULTS
Patients
The baseline data of the patients are summarized in Table 5.
Compared with the SR group, the inner diameter of theLength (bp) Annealing temperature (C)
256 58
214 60
30 410 Changing
-30
n II receptor type 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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TABLE 2. The comparison of AT-R subtype mRNA expression
between the AF and SR groups
AT1R AT2R
Group RA LA RA LA
AF 1.667  0.209 1.736  0.170 2.043  0.629 1.593  0.283
SR 1.766  0.379 1.507  0.346 1.842  0.583 1.573  0.306
P value .36 .028 .317 .833
AT-R, Angiotensin II receptor; AF, atrial fibrillation; SR, sinus rhythm; AT1-R, angio-
tensin II receptor type 1; AT2-R, angiotensin II receptor type 2; RA, right atrium; LA,
left atrium.
TABLE 3. The calculated IOD of AT-1R or AT2-R protein in the AF
and SR groups (3103)
AT1-R AT2-R
Group RA LA RA LA
AF 47.30  14.85 69.17  15.52* 82.54  11.60 79.92  8.52
SR 45.91  13.59 56.64  11.76 88.79  14.92 80.73  26.07
P value .771 .011 .152 .79
IOD, Integrated optical density; AT1-R, angiotensin II receptor type 1; AT2-R, angio-
tensin II receptor type 2; AF, atrial fibrillation; SR, sinus rhythm; RA, right atrium; LA,
left atrium.
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DLA was significantly increased in patients of the AF group.
However, there were no significant differences in the inner
diameter between the left and right ventricles or the RAs
in left ventricular ejection fraction and pulmonary arterial
pressure between the 2 groups. However, the patients in
the AF group had a slightly higher pulmonary artery pres-
sure than the patients in SR.RT–PCR Results
The level of AT1R mRNA expression in the LA was
highly increased in patients with AF compared with that
seen in those with SR (P ¼ .028), whereas the change in
AT2R mRNA expression in the LA was not statistically sig-
nificant (P¼ .36, Figure 2). The data of angiotensin II recep-
tor subtypes’ mRNA levels in the RA did not exhibit any
obvious changes either in AT1R or AT2R expression in pa-
tients with AF versus those with SR (Table 2).Immunohistochemistry Results
AT2-R protein expression in LA or RA tissue detected by
means of immunohistochemical staining showed no differ-
ence between the AF and SR groups (Figure 3). Expression
of AT2-R protein was not comparable between the patients
with AF and those with SR (LA: AF vs SR, P¼ .79; RA: AF
vs RA, P ¼ .15). The AT1-R protein expression in the LA
was higher in patients of the AF group (Figure 4, C) com-
pared with that seen in patients in the SR group (P ¼ .01;
Figure 4, D), but there is no significant difference for
AT1-R protein expression in the RA between the 2 groups
(P ¼ .77).TABLE 4. The comparison of AT-R subtype protein expression
between the AF and SR groups
AT1-R AT2-R
Group RA LA RA LA
AF 0.222  0.046 0.274  0.062* 0.297  0.057 0.271  0.064
SR 0.206  0.055 0.226  0.052 0.334  0.060 0.265  0.043
P value .326 .021 .064 .754
AT-R, Angiotensin II receptor; AF, atrial fibrillation; SR, sinus rhythm; AT1-R, angio-
tensin II receptor type 1; AT2-R, angiotensin II receptor type 2; RA, right atrium; LA,
left atrium.Western Blot Analysis Results
AT2-R protein expression in LA or RA tissue analyzed
by means of Western blotting showed no difference be-
tween the AF and SR groups (Figure 5, A, and Figure 1;
LA: AF vs SR, P ¼ .75; RA: AF vs RA, P ¼ .06). The
AT1-R protein expression in the LAs of the AF group
was higher than that in the LAs of the SR group (Figure 5,
B, and Figure 1; P ¼ .02), but there is no significant differ-
ence in AT1-R protein expression in RAs between the 2
groups (P ¼ .33).300 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
It has been well documented that AF can cause atrial re-
modeling, which can promote AF initiation and mainte-
nance.3-5 There are 2 types of atrial remodeling: structural
remodeling and electrical remodeling. Structural remodeling
includes significant changes in atrial tissue, such as accumu-
lation of increased amounts of fibrous tissue and collagen.
Electrical remodeling refers to any change in electrophysio-
logic function that promotes AF initiation and maintenance.
The RAS is one of the most important neuroendocrine sys-
tems in the organism and plays an important role in adjusting
the homeostasis of fluid balance and the cardiovascular sys-
tem. Its overactivation during AF has been well known.
Serum aldosterone levels have been shown to decrease in
patients with AF after restoration of SR, which reflects the
activation of the RAS in patients with AF.6 Goette and col-
leagues7 measured the activity of angiotensin-converting
enzyme (ACE) in human atrial appendages from patients
with AF or SR undergoing cardiac surgery and found
a 3-fold increase in ACE activity in patients with permanent
AF compared with that seen in those with SR. AF leads to
RAS activation, which seems to play a critical role in atrial
electrical and structural remodeling. Angiotensin II, as the
most important hormone of the RAS, is involved in the reg-
ulation of cardiovascular function through expression of its
type 1 and type 2 receptors. We found significant upregula-
tion of AT1-R in LA tissue of the AF group compared with
that seen in the SR group. Interestingly, there is no signifi-
cant difference in AT2-R expression in the LA tissue be-
tween the 2 groups. Therefore we believe that the AT1-R
upregulation might be necessary for the process of atrialery c August 2010
FIGURE 1. Bar graph forWestern blot analysis results. LA, Left atrium; RA, right atrium; AF, atrial fibrillation; SR, sinus rhythm; Ang II, angiotensin II; AT1,
angiotensin II receptor type 1; AT2, angiotensin II receptor type 2.
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gravation of AF. The cascade reactions activated by angio-
tensin II through AT1-R can result in increasing
expression of cell-cycle and cytokine-regulating genes.
The latter can induce the activity of mitogenic signaling
pathways, such as mitogen-activated protein kinase and Ja-
nus kinase/signal transducer and activator of transcription,
which can ultimately lead to activation of transcription fac-
tors controlling the expression of structural and cell-cycle
regulatory proteins and cause fibroblast proliferation, extra-
cellular matrix deposition, apoptotic changes, and intracellu-
lar communication alterations.8,9 Atrial fibrosis is probably
the most critical component of the remodeling process in pa-
tients with AF.10,11 The fibrosis is characterized by a marked
slowing in cardiac impulse propagation that might favor re-
entrant circuits in ‘‘microregions’’ where AF might persist,
which is considered to be an irreversible role in the progres-
sion of these pathophysiologic changes with AF, especially
persistent AF. Moexipril or enalaprilat, an ACEI, can inhibit
proliferation of cardiac fibroblasts induced by angiotensin II
according to their relative potency of ACE inhibition in vi-
tro.9 Recently, there is increasing evidence that blocking
the RAS with ACEIs or ARBs has a positive role in prevent-
ing new onset of AF and maintaining SR in patients with re-
current AF.12,13 In the Losartan Intervention for End-point
Reduction in Hypertension trial,14 the use of the ARB losar-
tan resulted in fewer cases of new-onset AF. For patients
with AF with left ventricular hypertrophy, losartan-based
therapy resulted in fewer strokes and cardiovascular
events.15 A post hoc ancillary analysis from a large random-TABLE 5. Clinical characteristics of patients in the AF and SR groups
Male (n) Female (n) Age (y) LAD (mm) RAD (mm
AF 6 18 53.88  9.83 58.58  7.91* 42.29  6
SR 4 11 48.27  10.37 48.67  5.39 39.26  5
AF, Atrial fibrillation; SR, sinus rhythm; LAD, left atrial inner diameter; RAD, right atrial inn
artery systolic pressure; MS, mitral stenosis; MI, mitral regurgitation. *Compared with the
The Journal of Thoracic and Caized trial of anticoagulation has demonstrated a significant
benefit of ACEI or ARB use among elderly patients with
AF. Patients aged 75 years taking ACEIs or ARBs had lower
mortality.16 However, there is also clinical evidence show-
ing that pretreatment with ACEIs does not prevent AF recur-
rences and might only improve acute success of electrical
cardioversion.17 However, meta-analysis confirms that
ACEIs and ARBs appeared to be very effective in the pre-
vention of AF, especially in patients with systolic left ven-
tricular dysfunction or left ventricular hypertrophy.18 The
benefits of ACEIs and ARBs in the treatment of AF might
be attributed to their antiremodeling effects.19,20 Boldt and
associates21 found that there was a significantly lower ex-
pression of collagen I in patients with chronic AF with
ACEI treatment and that the microcapillaries were signifi-
cantly rare in cases of AF without ACEIs. Therefore ACEI
treatment can attenuate atrial structural remodeling and pre-
vent the loss of atrial microcapillaries. In addition, a recent
animal experiment proved that both cilazapril and valsartan
can inhibit calpain I upregulation, suppress atrial structural
remodeling, and prevent the induction and promotion of
AF in dogs undergoing persistent rapid atrial pacing.22 De-
spite much progress in the study of the molecular mecha-
nism of AF treatment with ACEIs or ARBs, the definite
signaling network of AF pathogenesis remains to be further
investigated.
In contrast to our study, it has been reported by Goette and
colleagues,1 who studied the regulation of angiotensin II re-
ceptor subtypes in patients with AF, that expression of type
1 receptor was downregulated. However, our findings areValve disease
) LVD (mm) EF (%) PA (mm Hg) MS MSþMI
.96 48.29  7.07 61.37  8.17 54.08  12.5 15 9
.79 49.06  8.46 58.93  7.12 47.8  14.80 9 6
er diameter; LVD, left ventricular inner diameter; EF, ejection fraction; PA, pulmonary
SR group: P< .05.
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FIGURE 2. Reverse transcriptionpolymerase chain reaction results. A and B, Left atrium; C and D, right atrium; 15, atrial fibrillation group; 610, sinus
rhythm group. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; AT1, angiotensin II receptor type 1; AT2, angiotensin II receptor type 2.
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expression of AT1-R receptors in LA tissue was highly in-
creased in patients with lone AF or AF caused by mitral
valve disease. The difference in these studies might be
caused by the variation of the enrolled patient population.
Our data suggest that upregulation of AT1-R in LA tissue
of patients with AF could be one of the molecular bases inFIGURE 3. Expression of angiotensin II receptor type 2 in the left or right atria
atrial tissue of the AF group; B, right atrial tissue of the SR group, group; C, left
magnification 10 3 20.)
302 The Journal of Thoracic and Cardiovascular Surgthe process of atrial structural remodeling. Further studies
are needed to distinguish the difference and changes of an-
giotensin II receptor subtype expression in AF of different
causes.
Taken together, many other lines of evidence have in-
creasingly indicated that angiotensin II might play a determi-
nant role in conditioning structural remodeling during AF.l tissues of the atrial fibrillation (AF) or sinus rhythm (SR) groups. A, Right
atrial tissue of the AF group; D, left atrial tissue of the SR group. (Original
ery c August 2010
FIGURE 4. Expression of angiotensin II receptor type 1 in left or right atrial tissues of the atrial fibrillation (AF) and sinus rhythm (SR) groups. A, Right atrial
tissue of the AF group; B, right atrial tissue of the SR group; C, left atrial tissue of the AF group; D, left atrial tissue of the SR group. (Original magnification 10
3 20). Angiotensin II receptor type 1 is strongly expressed in left atria of the AF group.
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rhythmic drugs from a conventional viewpoint, their capa-
bility of reducing ventricular arrhythmias and sudden
cardiac death in patients with previous myocardial infarction
and heart failure has long been recognized. Both experimen-
tal and clinical data have confirmed the proarrhythmic role
of the RAS and demonstrated an antiarrhythmic effect of
ACEIs and AT1-R receptor blockers.15,23
Our current study has demonstrated that the expression of
AT1-R mRNA and protein in the LAs of patients with AFFIGURE 5. A, Protein expression of angiotensin II receptor type 2 (AT2)
in the left (LA) or right atrial (RA) tissues of the atrial fibrillation (AF) or si-
nus rhythm (SR) groups. B, Protein expression of angiotensin II receptor
type 1 (AT1) in the LA or RA tissues of the AF or SR groups.
The Journal of Thoracic and Cacaused by rheumatic valve disease is significantly increased.
This might indicate that there is a possible pathophysiologic
role for the RAS in AF. A series of effects mediated by the
activation of AT1-R might be one of the molecular mecha-
nisms involved in the process of atrial remodeling in AF.
In any case, the dissection of hierarchic signaling pathways
in atrial remodeling of AF needs to be further pursued.
This was a single-center observational clinical study on
AF caused by rheumatic valve disease. Rheumatic valve dis-
ease is the most common cause of AF. All the patients en-
rolled in this study had serious rheumatic valvular damage,
which could contribute to atrial remodeling. However, in
other forms of AF, such as AF without rheumatic valvular
disease or with other heart structural defects, the related
mechanisms of initiation, persistence, and recurrence in
these cases of AF remain to be investigated in future studies.
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